TY - JOUR T1 - Age specificity of cases and attack rate of novel coronavirus disease (COVID-19) JF - medRxiv DO - 10.1101/2020.03.09.20033142 SP - 2020.03.09.20033142 AU - Kenji Mizumoto AU - Ryosuke Omori AU - Hiroshi Nishiura Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/13/2020.03.09.20033142.abstract N2 - Age distribution of the cases with novel coronavirus disease (COVID-19) is rather different from that of influenza. In China, there were few reported cases among children [1] and serious or fatal child cases were also very infrequent. The age specificity is particularly important in designing details of social distancing, including school closure, as interventions, which is now recognized as the mainstream of interventions against COVID-19. Investigating the details of contacts, substantial susceptibility among children was demonstrated [2], but further insights into underlying mechanisms should be explored. Here we examined the age distribution of COVID-19 cases in Japan from January to March, 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers, H.N.: 17H04701, 17H05808, 18H04895 and 19H01074; K.M.: 18K17368], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. ER -